Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) EPS (Basic) (2021 - 2025)

Historic EPS (Basic) for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $0.5.

  • SAB Biotherapeutics' EPS (Basic) rose 14464.29% to $0.5 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 6222.22%. This contributed to the annual value of -$3.68 for FY2024, which is 5180.21% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' EPS (Basic) is $0.5, which was up 14464.29% from -$1.09 recorded in Q2 2025.
  • SAB Biotherapeutics' EPS (Basic)'s 5-year high stood at $0.5 during Q3 2025, with a 5-year trough of -$3.85 in Q4 2023.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.56 (2025), whereas its average is -$0.8.
  • As far as peak fluctuations go, SAB Biotherapeutics' EPS (Basic) crashed by 740000.0% in 2023, and later soared by 14464.29% in 2025.
  • SAB Biotherapeutics' EPS (Basic) (Quarter) stood at -$0.41 in 2021, then plummeted by 341.27% to -$1.81 in 2022, then plummeted by 112.8% to -$3.85 in 2023, then surged by 68.04% to -$1.23 in 2024, then skyrocketed by 140.64% to $0.5 in 2025.
  • Its EPS (Basic) stands at $0.5 for Q3 2025, versus -$1.09 for Q2 2025 and -$0.56 for Q1 2025.